{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:09:58Z","timestamp":1790651398211,"version":"4.1.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,2,8]],"date-time":"2014-02-08T00:00:00Z","timestamp":1391817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,2,8]],"date-time":"2014-02-08T00:00:00Z","timestamp":1391817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s11940-014-0283-8","type":"journal-article","created":{"date-parts":[[2014,2,7]],"date-time":"2014-02-07T02:04:11Z","timestamp":1391738651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Treatment of MuSK-Associated Myasthenia Gravis"],"prefix":"10.1007","volume":"16","author":[{"given":"Khalid","family":"El-Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefah","family":"Al-Hayk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Yahya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duha","family":"Al-Shorafat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said S.","family":"Dahbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,8]]},"reference":[{"key":"283_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<453::AID-MUS3>3.0.CO;2-O","volume":"23","author":"JM Lindstrom","year":"2000","unstructured":"Lindstrom JM. Acetylcholine receptors and myasthenia gravis. Muscle Nerve. 2000;23:453\u201377.","journal-title":"Muscle Nerve"},{"key":"283_CR2","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","volume":"26","author":"JM Lindstrom","year":"1976","unstructured":"Lindstrom JM, Seybold ME, Lennon VA, et al. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976;26:1054\u20139.","journal-title":"Neurology"},{"key":"283_CR3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/mus.21533","volume":"41","author":"M Pasnoor","year":"2010","unstructured":"Pasnoor M, Wolfe G, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve. 2010;41:370\u20134.","journal-title":"Muscle Nerve"},{"key":"283_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","volume":"44","author":"JF Guptill","year":"2011","unstructured":"Guptill JF, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical finding and response to therapy in two large cohorts. Muscle Nerve. 2011;44:36\u201340. A retrospective review of 110 MMG patients in two centers in the USA and Italy confirming female predominance and frequent oculobulbar weakness and crises. The response to treatment of various immunomodulatory\/immunosuppressive treatments in MMG was evaluated confirming good response to TPE. This study included one of the largest numbers of MMG patients evaluated.","journal-title":"Muscle Nerve"},{"key":"283_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1196\/annals.1405.005","volume":"1132","author":"GI Wolfe","year":"2008","unstructured":"Wolfe GI, Oh SJ. Clinical phenotype of muscle-specific tyrosine kinase antibody positive myasthenia gravis. Ann N Y Acad Sci. 2008;1132:71\u20135.","journal-title":"Ann N Y Acad Sci"},{"key":"283_CR6","first-page":"233","volume":"178","author":"A Vincent","year":"2006","unstructured":"Vincent A, Lang B. The prevalence of MuSK antibody positive myasthenia gravis worldwide. J Neuroimmunol. 2006;178:233.","journal-title":"J Neuroimmunol"},{"key":"283_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1196\/annals.1405.020","volume":"1132","author":"A Vincent","year":"2008","unstructured":"Vincent A, Leite MI, Farrugia ME, et al. Myasthenia gravis seronegative for acetylcholine receptor antibody. Ann N Y Acad Sci. 2008;1132:84\u201392.","journal-title":"Ann N Y Acad Sci"},{"key":"283_CR8","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","volume":"60","author":"DB Sanders","year":"2003","unstructured":"Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60:1978\u201380.","journal-title":"Neurology"},{"key":"283_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7:365\u20138.","journal-title":"Nat Med"},{"key":"283_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/mus.20069","volume":"30","author":"L Zhou","year":"2004","unstructured":"Zhou L, McConville J, Chaudhry V, et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and \u2013negative myasthenic patients. Muscle Nerve. 2004;30:55\u201360.","journal-title":"Muscle Nerve"},{"key":"283_CR11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","volume":"68","author":"F Deymeer","year":"2007","unstructured":"Deymeer F, Gungor-Tuncer O, et al. Clinical comparison of anti-MuSK- vs antiAChR-positive and seronegative myasthenia gravis. Neurology. 2007;68:609\u201311.","journal-title":"Neurology"},{"key":"283_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","volume":"67","author":"E Bartoccioni","year":"2006","unstructured":"Bartoccioni E, Scuderi F, Minicuci GM, et al. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology. 2006;67:505\u20137.","journal-title":"Neurology"},{"key":"283_CR13","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/WCO.0b013e32833c0982","volume":"23","author":"JT Guptill","year":"2010","unstructured":"Guptill JT, Sanders DB. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol. 2010;23:530\u20135.","journal-title":"Curr Opin Neurol"},{"key":"283_CR14","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.autrev.2013.03.004","volume":"12","author":"A Evoli","year":"2013","unstructured":"Evoli A, Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle specific kinase. Autoimmun Rev. 2013;12:913\u201335. An excellent review of the clinical phenotypes, diagnosis and treatment of MMG by experts in the field.","journal-title":"Autoimmun Rev"},{"key":"283_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1749-6632.2012.06781.x","volume":"1274","author":"A Evoli","year":"2012","unstructured":"Evoli A, Alboini PE, Bisonni A, et al. Management challenges in muscle specific tyrosine kinase myasthenia gravis. Ann N Y Acad Sci. 2012;1274:86\u201391. An excellent review of the current clinical, diagnostic and treatment challenges of MMG patients.","journal-title":"Ann N Y Acad Sci"},{"key":"283_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jneuroim.2008.05.032","volume":"201\u2013202","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, Juel VC. MuSK-antibody positive myasthenia gravis. Questions from the clinic. J Neuroimmunol. 2008;201\u2013202:85\u20139.","journal-title":"J Neuroimmunol"},{"key":"283_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1196\/annals.1405.012","volume":"1132","author":"A Evoli","year":"2008","unstructured":"Evoli A, Bianchi MR, Riso R, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci. 2008;1132:76\u201383.","journal-title":"Ann N Y Acad Sci"},{"key":"283_CR18","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1136\/jnnp.2004.052415","volume":"76","author":"D Lavrnic","year":"2005","unstructured":"Lavrnic D, Losen M, Vujic A, et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry. 2005;76:1099\u2013102.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"283_CR19","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1093\/brain\/awg223","volume":"126","author":"A Evoli","year":"2003","unstructured":"Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126:2304\u201311.","journal-title":"Brain"},{"key":"283_CR20","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.clinph.2005.06.003","volume":"116","author":"DE Stickler","year":"2005","unstructured":"Stickler DE, Massey JM, Sanders DB. MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol. 2005;116:2065\u20138.","journal-title":"Clin Neurophysiol"},{"key":"283_CR21","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1212\/01.wnl.0000183145.91579.74","volume":"65","author":"Y Hatanaka","year":"2005","unstructured":"Hatanaka Y, Hemmi S, Morgan MB, et al. Nonresponsiveness to anticholinesterase agents in patients with anti-MuSK-antibody-positive MG. Neurology. 2005;65:1508\u20139.","journal-title":"Neurology"},{"key":"283_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3988\/jcn.2009.5.2.53","volume":"5","author":"SJ Oh","year":"2009","unstructured":"Oh SJ. Muscle specific receptor tyrosine kinase antibody positive myasthenia gravis current status. J Clin Neurol. 2009;5:53\u201364.","journal-title":"J Clin Neurol"},{"key":"283_CR23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1600-0404.2006.00721.x","volume":"115","author":"S Kuwabara","year":"2007","unstructured":"Kuwabara S, Nemoto Y, Misawa S, et al. Anti-MuSK-positive myasthenia gravis: neuromuscular transmission failure in facial and limb muscles. Acta Neurol Scand. 2007;115:126\u20138.","journal-title":"Acta Neurol Scand"},{"key":"283_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/mus.20491","volume":"33","author":"ME Farrugia","year":"2006","unstructured":"Farrugia ME, Kennett RP, Newsom-Davis J, et al. Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis. Muscle Nerve. 2006;33:568\u201370.","journal-title":"Muscle Nerve"},{"key":"283_CR25","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.clinph.2006.03.028","volume":"117","author":"PA Rostedt","year":"2006","unstructured":"Rostedt PA, Ahlqvist K, Bartoccioni E, et al. Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes. Clin Neurophysiol. 2006;117:1434\u201343.","journal-title":"Clin Neurophysiol"},{"key":"283_CR26","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1212\/01.WNL.0000150587.71497.B6","volume":"64","author":"L Lauriola","year":"2005","unstructured":"Lauriola L, Ranelletti F, Maggiano N, et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology. 2005;64:536\u20138.","journal-title":"Neurology"},{"key":"283_CR27","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/ana.20386","volume":"57","author":"MI Leite","year":"2005","unstructured":"Leite MI, Str\u00f6bel P, Jones M, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol. 2005;57:444\u20138","journal-title":"Ann Neurol"},{"key":"283_CR28","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1212\/WNL.65.5.782","volume":"65","author":"E Saka","year":"2005","unstructured":"Saka E, Topcuoglu MA, Akkaya B, et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology. 2005;65:782\u20133.","journal-title":"Neurology"},{"key":"283_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11940-005-0001-7","volume":"7","author":"VC Juel","year":"2005","unstructured":"Juel VC, Massey JM. Autoimmune myasthenia gravis: recommendations for treatment and immunologic modulation. Curr Treat Options Neurol. 2005;7:3\u201314.","journal-title":"Curr Treat Options Neurol"},{"key":"283_CR30","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/mus.21319","volume":"39","author":"AR Punga","year":"2009","unstructured":"Punga AR, St\u00e5lberg EV. Acetylcholinesterase inhibitors in MG: to be or not to be? Muscle Nerve. 2009;39:724.","journal-title":"Muscle Nerve"},{"key":"283_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pediatrneurol.2012.07.008","volume":"48","author":"CM Ionita","year":"2013","unstructured":"Ionita CM, Acsadi G. Management of juvenile myasthenia gravis. Pediatr Neurol. 2013;48:95.","journal-title":"Pediatr Neurol"},{"key":"283_CR32","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/mus.21195","volume":"39","author":"LM Chiang","year":"2009","unstructured":"Chiang LM, Darras BT, Kang PB. Juvenile myasthenia gravis. Muscle Nerve. 2009;39:423.","journal-title":"Muscle Nerve"},{"key":"283_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/mus.20515","volume":"34","author":"AR Punga","year":"2006","unstructured":"Punga AR, Flink R, Askmark H, St\u00e5lberg EV. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve. 2006;34:111\u20135.","journal-title":"Muscle Nerve"},{"key":"283_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00018-005-5390-y","volume":"63","author":"MJ Herold","year":"2006","unstructured":"Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci. 2006;63:60\u201372.","journal-title":"Cell Mol Life Sci"},{"key":"283_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-0039.2006.00599.x","volume":"68","author":"I Rogatsky","year":"2006","unstructured":"Rogatsky I, Ivashkiv LB. Glucocorticoid modulation of cytokine signaling. Tissue Antigens. 2006;68:1\u201312.","journal-title":"Tissue Antigens"},{"key":"283_CR36","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/08916930903518107","volume":"43","author":"DB Sanders","year":"2010","unstructured":"Sanders DB, Evoli A. Immunosuppressive treatment of myasthenia gravis. Autoimmunity. 2010;43:428\u201335.","journal-title":"Autoimmunity"},{"key":"283_CR37","doi-asserted-by":"crossref","unstructured":"Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005; 18(2) (Apr).","DOI":"10.1002\/14651858.CD002828.pub2"},{"key":"283_CR38","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","volume":"61","author":"DP Richman","year":"2003","unstructured":"Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology. 2003;61:1652\u201361.","journal-title":"Neurology"},{"key":"283_CR39","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","volume":"15","author":"RM Pascuzzi","year":"1984","unstructured":"Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15:291\u20138.","journal-title":"Ann Neurol"},{"key":"283_CR40","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1212\/WNL.36.5.729","volume":"36","author":"RG Miller","year":"1986","unstructured":"Miller RG, Milner-Brown HS, Mirka A. Prednisone induced worsening of neuromuscular function in myasthenia gravis. Neurology. 1986;36:729\u201332.","journal-title":"Neurology"},{"key":"283_CR41","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/BF00314245","volume":"235","author":"R Mantegazza","year":"1988","unstructured":"Mantegazza R, Antozzi C, Peluchetti D, et al. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol. 1988;235:449\u201353.","journal-title":"J Neurol"},{"key":"283_CR42","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/ncpneuro0810","volume":"4","author":"S Sathasivam","year":"2008","unstructured":"Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol. 2008;4:317\u201327.","journal-title":"Nat Clin Pract Neurol"},{"key":"283_CR43","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50:1778\u201383.","journal-title":"Neurology"},{"key":"283_CR44","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17:893\u2013902.","journal-title":"Eur J Neurol"},{"key":"283_CR45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1055\/s-0032-1329200","volume":"32","author":"NJ Silvestri","year":"2012","unstructured":"Silvestri NJ, Wolfe GI. Myasthenia gravis. Semin Neurol. 2012;32:215\u201326.","journal-title":"Semin Neurol"},{"key":"283_CR46","doi-asserted-by":"publisher","unstructured":"Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol. 2013, Aug 21. doi:10.1111\/bcp.12226.","DOI":"10.1111\/bcp.12226"},{"key":"283_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1212\/WNL.36.1.35","volume":"36","author":"JT Kissel","year":"1986","unstructured":"Kissel JT, Levy RJ, Mendell JR, Griggs RC. Azathioprine toxicity in neuromuscular disease. Neurology. 1986;36:35\u20139.","journal-title":"Neurology"},{"key":"283_CR48","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/1531-8249(200005)47:5<682::AID-ANA24>3.0.CO;2-Z","volume":"47","author":"U Herrlinger","year":"2000","unstructured":"Herrlinger U, Weller M, Dichgans J, Melms A. Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis. Ann Neurol. 2000;47:682\u20133.","journal-title":"Ann Neurol"},{"key":"283_CR49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1212\/WNL.56.1.94","volume":"56","author":"V Chaudhry","year":"2001","unstructured":"Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology. 2001;56:94\u20136.","journal-title":"Neurology"},{"key":"283_CR50","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1212\/WNL.56.1.97","volume":"56","author":"E Ciafaloni","year":"2001","unstructured":"Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology. 2001;56:97\u20139.","journal-title":"Neurology"},{"key":"283_CR51","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","volume":"61","author":"MN Meriggioli","year":"2003","unstructured":"Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil in the treatment of myasthenia gravis: an analysis of efficacy, safety and tolerability. Neurology. 2003;61:1438\u201340.","journal-title":"Neurology"},{"key":"283_CR52","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/mus.21640","volume":"41","author":"MK Hehir","year":"2010","unstructured":"Hehir MK, Burns TM, Alpers JP, et al. Mycophenolate mofetil in AChR-antibody positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve. 2010;41:593\u20138.","journal-title":"Muscle Nerve"},{"key":"283_CR53","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","volume":"71","author":"The Muscle Study Group","year":"2008","unstructured":"The Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71:394\u20139.","journal-title":"Neurology"},{"key":"283_CR54","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, McDermott M, Thornton C, et al. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71:394\u20139.","journal-title":"Neurology"},{"key":"283_CR55","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1196\/annals.1405.031","volume":"1132","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, Siddiqi ZA. Lessons from two trials of mycophenolate mofetil in myasthenia gravis. Ann N Y Acad Sci. 2008;1132:249\u201353.","journal-title":"Ann N Y Acad Sci"},{"key":"283_CR56","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1212\/01.wnl.0000173031.56429.04","volume":"65","author":"S Vernino","year":"2005","unstructured":"Vernino S, Salomao DR, Habermann TM, O'Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology. 2005;65:639\u201341.","journal-title":"Neurology"},{"key":"283_CR57","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1097\/TP.0b013e31818b62c8","volume":"86","author":"RT Neff","year":"2008","unstructured":"Neff RT, Hurst FP, Falta EM, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation. 2008;86:1474\u20138.","journal-title":"Transplantation"},{"key":"283_CR58","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM198703193161205","volume":"316","author":"RSA Tindall","year":"1987","unstructured":"Tindall RSA, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316:719\u201324.","journal-title":"N Engl J Med"},{"key":"283_CR59","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","volume":"681","author":"RSA Tindall","year":"1993","unstructured":"Tindall RSA, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993;681:539\u201351.","journal-title":"Ann N Y Acad Sci"},{"key":"283_CR60","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/WNL.55.3.448","volume":"55","author":"E Ciafaloni","year":"2000","unstructured":"Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology. 2000;55:448\u201350.","journal-title":"Neurology"},{"key":"283_CR61","first-page":"110","volume":"40","author":"DC Rappaport","year":"1989","unstructured":"Rappaport DC, Weisbrod GL, Herman SJ. Cyclosporine-induced lymphoma following a unilateral lung transplant. The Toronto Lung Transplant Group. Can Assoc Radiol J. 1989;40:110\u20131.","journal-title":"Can Assoc Radiol J"},{"key":"283_CR62","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1212\/WNL.31.1.32","volume":"31","author":"MC Perez","year":"1981","unstructured":"Perez MC, Buot WL, Mercado-Danguilan C, et al. Stable remissions in myasthenia gravis. Neurology. 1981;31:32\u20137.","journal-title":"Neurology"},{"key":"283_CR63","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mus.10133","volume":"26","author":"LG De Feo","year":"2002","unstructured":"De Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve. 2002;26:31\u20136.","journal-title":"Muscle Nerve"},{"key":"283_CR64","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ana.10400","volume":"53","author":"DB Drachman","year":"2003","unstructured":"Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: \u201crebooting\u201d with high-dose cyclophosphamide. Ann Neurol. 2003;53:29\u201334.","journal-title":"Ann Neurol"},{"key":"283_CR65","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1196\/annals.1405.033","volume":"1132","author":"DB Drachman","year":"2008","unstructured":"Drachman DB, Adams RN, Hu R, et al. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci. 2008;1132:305\u201314.","journal-title":"Ann N Y Acad Sci"},{"key":"283_CR66","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/mus.20411","volume":"33","author":"PT Lin","year":"2006","unstructured":"Lin PT, Martin BA, Weinacker AB, et al. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve. 2006;33:433\u20135.","journal-title":"Muscle Nerve"},{"key":"283_CR67","doi-asserted-by":"publisher","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","volume":"124","author":"C Talar-Williams","year":"1996","unstructured":"Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener Granulomatosis. Ann Intern Med. 1996;124:477\u201384.","journal-title":"Ann Intern Med"},{"key":"283_CR68","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/mus.20479","volume":"33","author":"B Hain","year":"2006","unstructured":"Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve. 2006;33:575\u201380.","journal-title":"Muscle Nerve"},{"key":"283_CR69","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/jnnp.2010.220475","volume":"82","author":"S Blum","year":"2011","unstructured":"Blum S, Gillis D, Brown H, et al. Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82:659\u201363.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"283_CR70","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","volume":"78","author":"J D\u00edaz-Manera","year":"2012","unstructured":"D\u00edaz-Manera J, Mart\u00ednez-Hern\u00e1ndez E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012;78:189\u201393. A clinical study on 17 MG patients, 6 of whom are MMG, demonstrating long-lasting response to treatment with Rituximab, and recommending this medication as an early option for those not responding to corticosteroids.","journal-title":"Neurology"},{"key":"283_CR71","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1055\/s-0032-1329200","volume":"32","author":"NJ Silvestri","year":"2012","unstructured":"Silvestri NJ, Wolfe GI. Myasthenia gravis. Semin Neurol. 2012;32:215\u201326.","journal-title":"Semin Neurol"},{"key":"283_CR72","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/mus.24063","volume":"48","author":"JS Yi","year":"2013","unstructured":"Yi JS, Decroos EC, Sanders DB, et al. Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment. Muscle Nerve. 2013;48:992\u20133.","journal-title":"Muscle Nerve"},{"key":"283_CR73","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"CS Tan","year":"2010","unstructured":"Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9:425\u201337.","journal-title":"Lancet Neurol"},{"key":"283_CR74","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/CND.0b013e318137a24b","volume":"8","author":"GI Wolfe","year":"2007","unstructured":"Wolfe GI, Trivedi JR, Oh SJ. Clinical review of muscle-specific tyrosine kinase-antibody positive myasthenia gravis. J Clin Neuromuscul Disord. 2007;8:217\u201324.","journal-title":"J Clin Neuromuscul Disord"},{"key":"283_CR75","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jca.21257","volume":"28","author":"AA Kaplan","year":"2013","unstructured":"Kaplan AA. Therapeutic plasma exchange: a technical and operational review. J Clin Apher. 2013;28:3\u201310.","journal-title":"J Clin Apher"},{"key":"283_CR76","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/jca.21225","volume":"27","author":"K Kalantari","year":"2012","unstructured":"Kalantari K. The choice of vascular access for therapeutic apheresis. J Clin Apher. 2012;27:153\u20139.","journal-title":"J Clin Apher"},{"key":"283_CR77","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000183148","volume":"36","author":"HJ Gurland","year":"1984","unstructured":"Gurland HJ, Lysaght MJ, Samtleben W, Schmidt B. Comparative evaluation of filters used in membrane plasmapheresis. Nephron. 1984;36:173\u201382.","journal-title":"Nephron"},{"key":"283_CR78","doi-asserted-by":"crossref","unstructured":"Gajdos P, Chevret S, Toyka K. Plasma exchange for generalized myasthenia gravis. Cochrane Database Syst Rev. 2002; Oct 21.","DOI":"10.1002\/14651858.CD002275"},{"key":"283_CR79","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1055\/s-2004-829595","volume":"24","author":"VC Juel","year":"2004","unstructured":"Juel VC. Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol. 2004;24:75\u201381.","journal-title":"Semin Neurol"},{"key":"283_CR80","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mus.23626","volume":"47","author":"H Ebadi","year":"2013","unstructured":"Ebadi H, Barth D, Bril V. Safety of plasma exchange therapy in patients with myasthenia gravis. Muscle Nerve. 2013;47:510\u20134.","journal-title":"Muscle Nerve"},{"key":"283_CR81","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1046\/j.1537-2995.1989.29289146829.x","volume":"29","author":"DMC Sutton","year":"1989","unstructured":"Sutton DMC, Nair RC, Rock NG, Canadian Apheresis Study Group. Complications of plasma exchange. Transfusion. 1989;29:124.","journal-title":"Transfusion"},{"key":"283_CR82","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1744-9987.2005.00319.x","volume":"9","author":"N Basic-Jukic","year":"2005","unstructured":"Basic-Jukic N, Kes P, Glavas-Boras S, et al. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial. 2005;9:391\u20135.","journal-title":"Ther Apher Dial"},{"key":"283_CR83","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/mus.23508","volume":"47","author":"JT Guptill","year":"2013","unstructured":"Guptill JT, Oakley D, Kuchibhatla M, et al. Retrospective study of complications of therapeutic plasma exchange in myasthenia. Muscle Nerve. 2013;47:170\u20136.","journal-title":"Muscle Nerve"},{"key":"283_CR84","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.22139","volume":"68","author":"A Mandawat","year":"2010","unstructured":"Mandawat A, Kaminski HJ, Cutter G, et al. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol. 2010;68:797\u2013805.","journal-title":"Ann Neurol"},{"key":"283_CR85","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.22327","volume":"45","author":"JT Guptill","year":"2012","unstructured":"Guptill JT, Sharma BK, Marano A, et al. Estimated cost of treating myasthenia gravis in an insured U.S. population. Muscle Nerve. 2012;45:363\u20136.","journal-title":"Muscle Nerve"},{"key":"283_CR86","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1472-6963-11-101","volume":"11","author":"JL Winters","year":"2011","unstructured":"Winters JL, Brown D, Hazard E, et al. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barr\u00e9 syndrome. BMC Health Serv Res. 2011;11:101.","journal-title":"BMC Health Serv Res"},{"key":"283_CR87","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/CND.0b013e31822c34dd","volume":"13","author":"C Heatwole","year":"2011","unstructured":"Heatwole C, Johnson N, Holloway R, Noyes K. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis. 2011;13:85\u201394.","journal-title":"J Clin Neuromuscul Dis"},{"key":"283_CR88","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","volume":"15","author":"I Elovaara","year":"2008","unstructured":"Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15:893\u2013908.","journal-title":"Eur J Neurol"},{"key":"283_CR89","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1056\/NEJM198602273140907","volume":"314","author":"AW Burks","year":"1986","unstructured":"Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. N Engl J Med. 1986;314:560\u20134.","journal-title":"N Engl J Med"},{"key":"283_CR90","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jaci.2011.06.047","volume":"129","author":"R Rachid","year":"2012","unstructured":"Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol. 2012;129:628\u201334.","journal-title":"J Allergy Clin Immunol"},{"key":"283_CR91","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.clineuro.2010.02.008","volume":"112","author":"JA Nadeau","year":"2010","unstructured":"Nadeau JA, Bhibhatbhan A, McDougall D, et al. Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular disorders. Clin Neurol Neurosurg. 2010;112:467\u20139.","journal-title":"Clin Neurol Neurosurg"},{"key":"283_CR92","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000354893","volume":"38","author":"J Dantal","year":"2013","unstructured":"Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol. 2013;38:275\u201384.","journal-title":"Am J Nephrol"},{"key":"283_CR93","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","volume":"6","author":"U Katz","year":"2007","unstructured":"Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007;6:257\u20139.","journal-title":"Autoimmun Rev"},{"key":"283_CR94","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1055\/s-2004-829596","volume":"24","author":"A Jaretzki III","year":"2004","unstructured":"Jaretzki III A, Steinglass KM, Sonett JR. Thymectomy in the management of myasthenia gravis. Semin Neurol. 2004;24:49\u201362.","journal-title":"Semin Neurol"},{"key":"283_CR95","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00000658-199709000-00012","volume":"226","author":"GB Bulkley","year":"1997","unstructured":"Bulkley GB, Bass KN, Stephenson GR, et al. Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis. Ann Surg. 1997;226:324\u201334.","journal-title":"Ann Surg"},{"key":"283_CR96","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jneuroim.2012.02.010","volume":"245","author":"S Mori","year":"2012","unstructured":"Mori S, Kishi M, Kubo S, et al. 3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis. J Neuroimmunol. 2012;245:75\u20138.","journal-title":"J Neuroimmunol"},{"key":"283_CR97","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1196\/annals.1405.000","volume":"1132","author":"JM Ponseti","year":"2008","unstructured":"Ponseti JM, Gamez J, Azem J, et al. Tacrolimus for myasthenia gravis a clinical study of 212 patients. Ann N Y Acad Sci. 2008;1132:254\u201363.","journal-title":"Ann N Y Acad Sci"},{"key":"283_CR98","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.clineuro.2004.07.013","volume":"107","author":"JM Ponseti","year":"2005","unstructured":"Ponseti JM, Azem J, Fort JM, et al. Benefits of FK506 (tacrolimus) for residual, cyclosporine- and prednisone-resistant myasthenia gravis: one-year follow up of an open-label study. Clin Neurol Neurosurg. 2005;107:187\u201390.","journal-title":"Clin Neurol Neurosurg"},{"key":"283_CR99","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","volume":"64","author":"JM Ponseti","year":"2005","unstructured":"Ponseti JM, Azem J, Fort JM, et al. Long-term results of tacrolimus in cyclosporine- and prednisone dependent myasthenia gravis. Neurology. 2005;64:1641\u20133.","journal-title":"Neurology"},{"key":"283_CR100","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1185\/030079907X188080","volume":"23","author":"JM Ponseti","year":"2007","unstructured":"Ponseti JM, Gamez J, Azem J, et al. Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study. Curr Med Res Opin. 2007;23:1269\u201378.","journal-title":"Curr Med Res Opin"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-014-0283-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11940-014-0283-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-014-0283-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-014-0283-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:59:05Z","timestamp":1659095945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11940-014-0283-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,8]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["283"],"URL":"https:\/\/doi.org\/10.1007\/s11940-014-0283-8","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,8]]},"assertion":[{"value":"8 February 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"283"}}